{"id":46273,"date":"2022-07-18T16:02:08","date_gmt":"2022-07-18T14:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/"},"modified":"2022-07-18T16:02:08","modified_gmt":"2022-07-18T14:02:08","slug":"johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/","title":{"rendered":"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022"},"content":{"rendered":"
\n

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ<\/a>) today announced that Michael (Mike) Ullmann will retire from his position as Executive Vice President, General Counsel at the end of this year, following 33 years of leadership and service to the Company. Throughout his distinguished career, Mr. Ullmann has worked with the organization\u2019s Board of Directors and partnered with four company CEOs to shape and grow Johnson & Johnson into the most broadly based healthcare company in the world.\n<\/p>\n

<\/a><\/p>\n

\nHe will be succeeded in this role by Elizabeth (Liz) Forminard, a strong Credo-based leader who has had an exceptional career with depth and breadth across the Company\u2019s Pharmaceutical, MedTech, and Consumer Health sectors. Ms. Forminard will also be appointed as a member of Johnson & Johnson\u2019s Executive Committee, effective October 17, 2022. Mr. Ullmann and Ms. Forminard will work together during a transition period until Mr. Ullmann\u2019s retirement at the end of this year.\n<\/p>\n

\n\u201cFor three decades, Mike set the standard for Credo leadership at the Company. I thank him for his unwavering commitment to help deliver on Our Purpose of advancing health for humanity,\u201d said Joaquin Duato, Chief Executive Officer, Johnson & Johnson. \u201cThroughout his tenure, Mike has guided the company through an evolving global environment with respect and clarity, always keeping our patients and customers at the center of all decisions.\u201d\n<\/p>\n

\nMr. Ullmann joined Johnson & Johnson as a mergers & acquisitions attorney in 1989 and has since held positions of increasing responsibility in the Company\u2019s Law Department, ultimately serving as General Counsel for the past 11 years. During this time, Mr. Ullmann has led the Company through complex matters while ensuring all Company standards and policies reflect the needs of a changing world and a new generation of employees, underscoring a commitment to diversity, equity and inclusion (DEI) and reinforcing the Company\u2019s dedication to the health of humanity. A dedicated advocate for DEI, he has also served as the executive sponsor for the Company\u2019s Hispanic and Latino employee resource group and as a member of the Leadership Council on Legal Diversity, an organization that works to build a more open and diverse legal profession.\n<\/p>\n

\nLiz Forminard has been with Johnson & Johnson for 16 years, having served as General Counsel across each of the Pharmaceutical, Consumer Health and MedTech sectors, as well as Worldwide Vice President leading the Corporate Governance function, and numerous other functional and business-facing roles during this time. Throughout her tenure on the Law Department Executive Committee (LDEC), Ms. Forminard has built and led global teams who share her passion for the role legal can play in driving innovation and influencing the external environment to enable positive patient outcomes. In her most recent role, Ms. Forminard served as General Counsel for the Pharmaceuticals Legal Group and member of the Pharmaceuticals Group Operating Committee, leading the legal function globally for the sector and for Johnson & Johnson Global External Innovation and Global Public Health, where she drove programs to ensure optimal, aligned intellectual property, regulatory and commercial strategies internally, and helped to shape the global healthcare environment externally.\n<\/p>\n

\n\u201cI\u2019m thrilled to appoint Liz to this important role and will lean on her strong business acumen and understanding of patient and customer needs during this pivotal time at our Company,\u201d said Mr. Duato. \u201cI\u2019m confident her distinguished experience and leadership will help us find new pathways to bring innovative healthcare solutions to those in need all over the world.\u201d\n<\/p>\n

\nAbout Johnson & Johnson<\/b>\n<\/p>\n

\nAt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.\n<\/p>\n

\nCautions Concerning Forward Looking Statements<\/b>\n<\/p>\n

\nThis press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A list and descriptions of risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov<\/a>, www.jnj.com<\/a> or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJohnson & Johnson
\n
media-relations@its.jnj.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced that Michael (Mike) Ullmann will retire from his position as Executive Vice President, General Counsel at the end of this year, following 33 years of leadership and service to the Company. Throughout his distinguished career, Mr. Ullmann has worked with the organization\u2019s Board of Directors … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46273","6":"format-standard","7":"category-industry"},"yoast_head":"\nJohnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced that Michael (Mike) Ullmann will retire from his position as Executive Vice President, General Counsel at the end of this year, following 33 years of leadership and service to the Company. Throughout his distinguished career, Mr. Ullmann has worked with the organization\u2019s Board of Directors ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-18T14:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220718005462\/en\/1516003\/21\/JNJ_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022\",\"datePublished\":\"2022-07-18T14:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/\"},\"wordCount\":907,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005462\\\/en\\\/1516003\\\/21\\\/JNJ_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/\",\"name\":\"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005462\\\/en\\\/1516003\\\/21\\\/JNJ_Logo.jpg\",\"datePublished\":\"2022-07-18T14:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005462\\\/en\\\/1516003\\\/21\\\/JNJ_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005462\\\/en\\\/1516003\\\/21\\\/JNJ_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/","og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 - Pharma Trend","og_description":"NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) today announced that Michael (Mike) Ullmann will retire from his position as Executive Vice President, General Counsel at the end of this year, following 33 years of leadership and service to the Company. Throughout his distinguished career, Mr. Ullmann has worked with the organization\u2019s Board of Directors ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-18T14:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220718005462\/en\/1516003\/21\/JNJ_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022","datePublished":"2022-07-18T14:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/"},"wordCount":907,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220718005462\/en\/1516003\/21\/JNJ_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/","url":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/","name":"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220718005462\/en\/1516003\/21\/JNJ_Logo.jpg","datePublished":"2022-07-18T14:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220718005462\/en\/1516003\/21\/JNJ_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220718005462\/en\/1516003\/21\/JNJ_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/johnson-elizabeth-forminard-named-general-counsel-effective-october-17-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Johnson & Johnson\u2019s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46273"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46273\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}